Ki67 as a prognostic marker in comparison with Gleason’s grading system in prostatic carcinoma

---

Original Article

Author Details : Rajeswari.K, Meenakshisundaram.K, Anushuya.G, Rajalakshmi.V

Volume : 3, Issue : 1, Year : 2016

Article Page : 92-95

Suggest article by email

Get Permission

---

Abstract

Background & Objectives: Prostatic carcinoma is the most common malignancy in males in the western countries and it is also on the rise in the developing countries like India. There are many markers studied in prostatic cancers, but the most extensively studied one is Ki-67, the proliferative marker.[1,2] Prostatic cancers with Ki-67 over expression are generally aggressive.[3,4] The aim of the study was to assess the proliferative status of the prostatic adenocarcinoma with Ki67 immunostaining and to compare and analyze the association with Gleason’s grading for the assessment of prognosis.
Materials & Methods: Forty six randomly selected patients who underwent transurethral resection of prostate, samples in the form of prostatic tru-cut biopsy and radical prostatectomy were studied. Gleason’s grading and scoring were done on every case. The sections were also immunostained with monoclonal antibodies against Ki-67 and expression of Ki-67 was studied. The obtained results were statistically analyzed.
Results & Interpretation: A strong statistically significant correlation was found between Ki 67 expression and Gleason’s score.
Conclusion: It is noteworthy that a significant correlation exists between the Gleason’s score and the expression of Ki-67 in our study. We observed a high expression of Ki-67 for tumours with Gleason’s score of 7 or above. Our results suggest that Ki-67 may be useful to serve as a prognostic predictor along with Gleason’s grading in prostatic carcinoma.

Keywords: Gleason’s grade, Ki-67, Prostatic cancer

How to cite : Rajeswari.k, Meenakshisundaram.k, Anushuya.g, Rajalakshmi.v, Ki67 as a prognostic marker in comparison with Gleason’s grading system in prostatic carcinoma. Indian J Pathol Oncol 2016;3(1):92-95

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.